» Articles » PMID: 26668470

Juxtacortical Osteosarcoma of the Mandible: Challenges in Diagnosis and Management

Overview
Date 2015 Dec 16
PMID 26668470
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Parosteal osteosarcoma (OS) of the jaw is a rare type of OS with peculiar clinical radiographic and microscopic features. The aim of this article was to report and discuss a case of high-grade parosteal OS in the mandible of a 35-year-old woman. The patient reported sensing mild pain and swelling in the retro molar area on the left side of the mouth for a period of 4 years, despite continuous dental treatment. The radiographic evaluation showed a mixed radiopaque/radiolucent lesion in the body of the left side of the mandible. Destruction of the mandibular cortex in that area was also observed. After the initial histological study, the patient underwent partial hemi-mandibulectomy. Microscopic findings showed a tumor exhibiting spindle cells with nuclear hyperchromasia, moderate pleomorphism, and irregular osteoid formation, with chondroid differentiation noted with tumor-free margins. The immunohistochemical analysis showed the expression of negativity to p53, human epidermal growth factor receptor 2/neu, and positivity to S-100. The diagnosis was high-grade parosteal OS of the jaw. The 4 years clinical and imaging postoperative follow-up showed no evidence of recurrence. The literature on this unusual pathologic entity reviewed and diagnostic challenges described.

Citing Articles

Clinical and Pathological Features of Osteosarcomas of the Jaws: A Retrospective Study.

Rodriguez-Molinero J, Pozo-Kreilinger J, Ruiz-Roca J, Lopez-Sanchez A, Cebrian-Carretero J Clin Pract. 2024; 14(3):965-979.

PMID: 38921255 PMC: 11202223. DOI: 10.3390/clinpract14030077.


Immunoexpression of Ki67, p53 and cyclin D1 in osteosarcomas.

Niculescu S, Grecu D, Simionescu C, Niculescu E, Stepan M, Stepan A Rom J Morphol Embryol. 2022; 62(3):743-750.

PMID: 35263402 PMC: 9019677. DOI: 10.47162/RJME.62.3.11.


Association between expression of nuclear receptor co-activator 5 protein and prognosis in postoperative patients with osteosarcoma.

Wu Y, Wu J, Dong Q, Guo N Oncol Lett. 2018; 15(2):1888-1892.

PMID: 29434886 PMC: 5776951. DOI: 10.3892/ol.2017.7513.

References
1.
Wanebo H, Koness R, Macfarlane J, Eilber F, Byers R, Elias E . Head and neck sarcoma: report of the Head and Neck Sarcoma Registry. Society of Head and Neck Surgeons Committee on Research. Head Neck. 1992; 14(1):1-7. DOI: 10.1002/hed.2880140102. View

2.
Smeele L, Kostense P, van der Waal I, Snow G . Effect of chemotherapy on survival of craniofacial osteosarcoma: a systematic review of 201 patients. J Clin Oncol. 1997; 15(1):363-7. DOI: 10.1200/JCO.1997.15.1.363. View

3.
Caron A, HAJDU S, Strong E . Osteogenic sarcoma of the facial and cranial bones. A review of forty-three cases. Am J Surg. 1971; 122(6):719-25. DOI: 10.1016/0002-9610(71)90434-x. View

4.
Mardinger O, Givol N, Talmi Y, Taicher S . Osteosarcoma of the jaw. The Chaim Sheba Medical Center experience. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001; 91(4):445-51. DOI: 10.1067/moe.2001.112330. View

5.
FORTEZA G, Colmenero B, Lopez-Barea F . Osteogenic sarcoma of the maxilla and mandible. Oral Surg Oral Med Oral Pathol. 1986; 62(2):179-84. DOI: 10.1016/0030-4220(86)90042-3. View